Search
forLearn
5 / 801 resultslearn HT-B
learn TDM-105795
learn PTT-6®
learn KB solution
Research
5 / 1000+ results
research Association between SQSTM1 dysregulation and risk in alopecia areata: a Mendelian randomization study
SQSTM1 gene issues may increase the risk of alopecia areata.
research Table 1_Association between SQSTM1 dysregulation and risk in alopecia areata: a Mendelian randomization study.docx
SQSTM1 is linked to increased risk of alopecia areata.
research RORA Regulates Autophagy in Hair Follicle Stem Cells by Upregulating the Expression Level of the Sqstm1 Gene
RORA boosts autophagy in hair follicle stem cells, potentially aiding hair growth.
research Autophagy is essential for maintaining the growth of a human (mini-)organ: Evidence from scalp hair follicle organ culture
Autophagy is important for human hair growth and health.
research Restoring neuropetide Y levels in the hypothalamus ameliorates premature aging phenotype in mice
Increasing neuropeptide Y in the brain can slow aging signs in mice.
Community Join
5 / 1000+ resultscommunity PTD-DBM Update: Q&A With Dr. Kang-Yell Choi
PTD-DBM is being explored for hair regrowth by targeting CXXC5, with clinical trials expected after pre-clinical studies. Users express anticipation and skepticism about its effectiveness.
community mallia therapeutics 8T3 scd83 molecule for ffa/lpp mainly and aga
A user applied the 8T3 product for hair loss, targeting LPP and AGA, and plans to update on its effectiveness. The product uses a saline buffered phosphate vehicle, suitable for those intolerant to ethanolic vehicles.
community Stemoxydine used for shortening the ugly duckling phase after HT?
The conversation is about whether stemoxydine can shorten the dormant phase after a hair transplant, known as the ugly duckling phase. There is skepticism about whether it actually works as claimed.
community HLT Megathread on HMI-115 (key takeaways in comments)
HMI-115, a newly discovered hair loss treatment that could potentially be effective for those with diffuse thinning and telogen effluvium. It is based on prolactin receptor antagonist signaling and has already undergone Phase I trials in women, with potential commercialization by 2027.
community Stemson Therapeutics Human Trial Starting in 2026
Stemson Therapeutics will start human trials for hair cloning in late 2025-2026. Product development is complete, and they are preparing for production and clinical trials.